{"id":"je-vax","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions (pain, erythema, swelling)"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL1812466","moleculeType":"Small molecule","molecularWeight":"297.74"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains a weakened strain of Japanese encephalitis virus that triggers both humoral and cellular immune responses without causing disease. This allows the body to develop protective antibodies and T-cell immunity against the virus, preventing infection or reducing disease severity upon exposure to wild-type virus.","oneSentence":"JE-VAX is a live attenuated vaccine that stimulates immune response against Japanese encephalitis virus.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:17:35.609Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of Japanese encephalitis in endemic regions"}]},"trialDetails":[{"nctId":"NCT06680128","phase":"PHASE1, PHASE2","title":"A Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis Messenger Ribonucleic Acid (mRNA) Vaccines (GBP560) in Healthy Adults","status":"RECRUITING","sponsor":"SK Bioscience Co., Ltd.","startDate":"2025-02-24","conditions":"Japanese Encephalitis Virus Disease","enrollment":402},{"nctId":"NCT02963909","phase":"PHASE1","title":"A Phase 1, First-in-human, Double-blinded, Randomized, Placebo-controlled Trial of a Zika Virus Purified Inactivated Vaccine (ZPIV) With Alum Adjuvant in Healthy Flavivirus-naive and Flavivirus-Primed Subjects.","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-11-01","conditions":"Zika Virus Infection","enrollment":75},{"nctId":"NCT01041573","phase":"PHASE3","title":"Safety and Immunogenicity of the Japanese Encephalitis Vaccine IC51 (IXIARO®) in a Pediatric Population","status":"COMPLETED","sponsor":"Valneva Austria GmbH","startDate":"2010-03","conditions":"Encephalitis","enrollment":1869},{"nctId":"NCT01047839","phase":"PHASE3","title":"Immunogenicity and Safety of the Japanese Encephalitis Vaccine IC51 (IXIARO®, JESPECT®) in a Pediatric Population in Non-endemic Countries","status":"COMPLETED","sponsor":"Valneva Austria GmbH","startDate":"2010-01","conditions":"Encephalitis","enrollment":100},{"nctId":"NCT01246479","phase":"PHASE3","title":"Long Term Immunity and Safety Following Vaccination With the JEV IC51 (IXIARO®, JESPECT®) in Pediatric Population In Non Endemic Countries. Uncontrolled, Ph3 FU-Study","status":"COMPLETED","sponsor":"Valneva Austria GmbH","startDate":"2010-10","conditions":"Japanese Encephalitis","enrollment":23},{"nctId":"NCT03971058","phase":"PHASE4","title":"Immune Responses After a Booster Immunisation With IXIARO® in Elderly Compared to Young Individuals.","status":"UNKNOWN","sponsor":"Medical University of Vienna","startDate":"2019-03-01","conditions":"Japanese Encephalitis Vaccine","enrollment":64},{"nctId":"NCT00740155","phase":"PHASE2","title":"Safety and Immunogenicity of Formulations of Dengue Vaccines in Healthy Flavivirus-Naïve Adults","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2008-08","conditions":"Dengue Virus, Dengue Fever, Dengue Hemorrhagic Fever","enrollment":154},{"nctId":"NCT01296360","phase":"PHASE3","title":"Open-label, Randomized Study in a Pediatric Population in a JEV (Japanese Encephalitis Virus)-Endemic Country","status":"COMPLETED","sponsor":"Valneva Austria GmbH","startDate":"2010-12","conditions":"Japanese Encephalitis","enrollment":300},{"nctId":"NCT00314145","phase":"PHASE3","title":"A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVax™-JE and JE-VAX","status":"COMPLETED","sponsor":"Sanofi","startDate":"2005-11","conditions":"Japanese Encephalitis","enrollment":820},{"nctId":"NCT00319592","phase":"PHASE2","title":"A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVaxTM-JE and JE-VAX","status":"COMPLETED","sponsor":"Sanofi","startDate":"2005-05","conditions":"Japanese Encephalitis","enrollment":60},{"nctId":"NCT01158599","phase":"PHASE4","title":"This is a Study to Assess the Safety and Immunogenicity of Ixiaro® (IC51) in an Elderly Population","status":"COMPLETED","sponsor":"Valneva Austria GmbH","startDate":"2010-06","conditions":"Japanese Encephalitis","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":28,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"JE-VAX®","genericName":"JE-VAX®","companyName":"Sanofi","companyId":"sanofi","modality":"Biologic","firstApprovalDate":"","aiSummary":"JE-VAX is a live attenuated vaccine that stimulates immune response against Japanese encephalitis virus. Used for Prevention of Japanese encephalitis in endemic regions.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}